{"groups":[{"description":"Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.","id":"FG000","title":"Conventional & Patient-specific Dosimetry"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"tumors not visible on imaging"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"Conventional Dosimetry"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"Patient-specific Dosimetry"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All NHL patients treated by either Bexxar or Zevalin"}